Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Venetoclax plus rituximab or obinutuzumab in CLL after alloHCT

Othman Al-Sawaf • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Obinutuzumab Rituximab Venetoclax

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the use of venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL). This was taken from the clinical data of 4 patients at his center, indicating that treatment with venetoclax is feasible and effective in patients with CLL and relapsed disease after alloHCT. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Othman Al-Sawaf

Treatment of Richter’s transformation: recent insights 1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
The expanding landscape of next-generation BTK inhibitors in CLL 1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
Fixed-duration treatment strategies for frontline and relapsed CLL 0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL 1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals